BENEFITS/ CLINICAL TRIALS The research interest in IGF-1 LR3 is primarily focused on its enhanced anabolic (tissue-building) and lipolytic (fat-burning) potency compared to the native hormone
Rakotomanomana, F
800-69-MERIT / 800-696-3748 SKU 029464516687 NDC 70069-0005-10 Manufacturer Number 70069000510 Login to see prices & order NDC Number 70069-0005-10 / 70069000510 Manufacturer: Somerset Therapeutics, LLC Application B12 Deficiencies Strength: 1,000mcg/mL Multiple Dose Vial Storage Requirements USP Controlled Room Temperature Type Intramuscular or Subcutaneous Volume 30 mL Related products DEPO-MEDROL 80MG/ML, 5ML, (METHYLPREDNISOLONE ACETATE INJ SUSPENSION, USP), MDV, NDC 00009030602 NON-RETURNABLE Login to see prices & order KENALOG-10 (TRIAMCINOLONE ACETONIDE INJ SUSPENSION, USP) MDV, 10MG/ML, 5ML Login to see prices & order KENALOG-40 (TRIAMCINOLONE ACETONIDE INJ SUSPENSION, USP), MDV 40MG/ML, 10ML Login to see prices & order FOLIC ACID INJECTION, USP, MDV, 5MG/ML, 10ML NDC 6332318410 Login to see prices & order Call 800 69 MERIT for pharmaceuticals, medical devices and related professional healthcare products
Patients who have an ischemic stroke in the morning, or onset of their active period, are not only at a greater risk for poor outcome based on the hyperfibrinolytic morning state, but additionally, response to thrombolytic intervention is less efficacious during the morning time points
